Question 1

What is thymopentin (TP-5) and how does it relate to thymopoietin?

Accepted Answer

Thymopentin (TP-5) is a synthetic pentapeptide consisting of five amino acids (Arg-Lys-Asp-Val-Tyr) that corresponds to positions 32-36 of the natural 49-amino-acid thymic hormone thymopoietin. Research by Gideon Goldstein at Sloan-Kettering showed that this short fragment retains the full T-cell differentiating activity of the complete thymopoietin molecule. The synthetic pentapeptide is more stable and practical to manufacture than the full-length protein, making it the clinically used form.

Question 2

What conditions is thymopentin approved to treat?

Accepted Answer

Thymopentin is approved in China for primary immunodeficiency, recurrent infections in immunocompromised patients, chronic hepatitis B (as adjunct therapy), and immune support during cancer chemotherapy. It has been used clinically in Italy and other European countries for immunodeficiency and rheumatoid arthritis, though European use has declined. It is not FDA-approved in the United States.

Question 3

How does thymopentin compare to Thymosin Alpha-1?

Accepted Answer

Both are thymic peptides that enhance T-cell immunity, but they differ in structure and evidence base. Thymosin Alpha-1 is a 28-amino-acid peptide approved in 30+ countries (as Zadaxin) with broader international RCT data, particularly for hepatitis B/C. Thymopentin is a shorter 5-amino-acid peptide with a larger clinical footprint in China but less international clinical trial data. Thymosin Alpha-1 has a longer half-life (~2 hours vs ~30 seconds for TP-5), potentially requiring less frequent dosing. Both share the goal of immune reconstitution but act through partially overlapping mechanisms.

Question 4

Why does thymopentin have such a short half-life?

Accepted Answer

TP-5's plasma half-life of approximately 30 seconds results from rapid enzymatic degradation by aminopeptidases and other serum proteases. As an unmodified linear pentapeptide, it is highly susceptible to proteolytic cleavage. Despite this short plasma half-life, the biological effects persist much longer because TP-5 triggers intracellular signaling cascades in T-cell precursors that continue after the peptide itself is cleared. This is why clinical dosing protocols of once daily or three times weekly produce sustained immunological effects.

Question 5

Is thymopentin safe? What are the side effects?

Accepted Answer

Thymopentin has a favorable safety profile across published clinical studies. The most commonly reported side effects are mild injection-site reactions (redness, pain, swelling) and occasional transient fever. Serious adverse events are rare in the published literature. The Sundal & Bertelletti (1994) rheumatoid arthritis trial (n=195) reported no significant difference in adverse event rates between TP-5 and placebo groups. However, as with any immune-modulating agent, use should be supervised by a physician, particularly in patients with autoimmune conditions where immune stimulation could theoretically exacerbate disease.

Question 6

Can thymopentin help during cancer chemotherapy?

Accepted Answer

Chinese clinical studies have evaluated thymopentin as an adjunct during chemotherapy for cancers including non-small-cell lung cancer and hepatocellular carcinoma. Results generally show that TP-5 can partially protect against chemotherapy-induced immune suppression — specifically, patients receiving TP-5 alongside chemotherapy maintained higher CD4+ T-cell counts and better CD4/CD8 ratios compared to chemotherapy-alone groups. Some studies also reported reduced incidence of infections and improved quality of life scores. These results are promising but most studies have been open-label with moderate sample sizes, and large multicenter RCTs are still needed.

Question 7

How is thymopentin administered and what is the standard dosing?

Accepted Answer

Thymopentin is administered via subcutaneous or intramuscular injection. The standard clinical dose ranges from 1 mg daily to 10 mg every other day, depending on the indication and national prescribing guidelines. For immune reconstitution, 1 mg subcutaneously three times weekly for 4-12 weeks is common. In Chinese oncology protocols, 1 mg daily intramuscular injection during chemotherapy cycles is typical. The peptide is supplied as a lyophilized powder that is reconstituted with sterile saline before injection.

Question 8

Why was thymopentin never approved by the FDA?

Accepted Answer

Ortho Pharmaceutical Corporation (a Johnson & Johnson subsidiary) pursued FDA approval for thymopentin in the 1980s, conducting clinical trials in rheumatoid arthritis and HIV/AIDS. The development program was discontinued before completing pivotal Phase III trials, likely due to a combination of the peptide's very short half-life (complicating pharmacokinetic optimization), the challenge of demonstrating clear clinical endpoints beyond biomarker improvements, and shifting commercial priorities. The lack of FDA approval reflects an incomplete regulatory pathway rather than evidence of inefficacy or safety concerns.

Question 9

Does thymopentin work for autoimmune diseases like rheumatoid arthritis?

Accepted Answer

Thymopentin was studied in rheumatoid arthritis based on its immunomodulatory rather than purely immunostimulatory properties. The Sundal & Bertelletti (1994) multicenter RCT in 195 RA patients found modest improvements in joint tenderness and swelling with TP-5 treatment, along with improved T-cell function markers. However, the clinical benefit was not dramatic enough to establish TP-5 as a standard RA therapy. The theoretical basis — that TP-5 can normalize dysregulated T-cell populations — remains sound, but the evidence base is insufficient to recommend it as a primary autoimmune treatment.

Question 10

How does thymopentin differ from thymalin and thymulin?

Accepted Answer

These are all thymic peptides but differ substantially. Thymopentin (TP-5) is a defined synthetic pentapeptide with a known sequence (RKDVY) and specific mechanism. Thymalin is a crude polypeptide extract from bovine thymus with undefined composition, primarily studied in Russian cohorts. Thymulin (formerly FTS, facteur thymique serique) is a zinc-dependent nonapeptide naturally secreted by thymic epithelial cells that requires zinc for biological activity. Thymopentin has the advantage of being a precisely defined synthetic molecule, while thymalin's crude extract nature makes standardization difficult and thymulin's zinc dependency adds pharmacological complexity.

Origin / Manufacturer	Synthetic
Active Components	Thymopentin (TP-5) pentapeptideMannitol (lyoprotectant)Sodium chloride
Storage	Store at 2–8°C, protect from light
Shelf Life	24 months
Form Factor	Lyophilized powder for injection

Thymopoietin (TP-5 / Thymopentin)

Specifications

Clinical Evidence

Frequently Asked Questions

Sources & References

Related Peptides

Thymalin (Thymic Polypeptide Complex)

Thymalin

Thymosin α1

Thymulin